This study attempts to evaluate the quality of Chinese formula granules by combined use of multi-component simultaneous quantitative analysis and bioassay. The rhubarb dispensing granules were used as the model drug for demonstrative study. The ultra-high performance liquid chromatography (UPLC) method was adopted for simultaneously quantitative determination of the 10 anthraquinone derivatives (such as aloe emodin-8-O-β-D-glucoside) in rhubarb dispensing granules; purgative biopotency of different batches of rhubarb dispensing granules was determined based on compound diphenoxylate tablets-induced mouse constipation model; blood activating biopotency of different batches of rhubarb dispensing granules was determined based on in vitro rat antiplatelet aggregation model; SPSS 22.0 statistical software was used for correlation analysis between 10 anthraquinone derivatives and purgative biopotency, blood activating biopotency. The results of multi-components simultaneous quantitative analysisshowed that there was a great difference in chemical characterizationand certain differences inpurgative biopotency and blood activating biopotency among 10 batches of rhubarb dispensing granules. The correlation analysis showed that the intensity of purgative biopotency was significantly correlated with the content of conjugated anthraquinone glycosides (P<0.01), and the intensity of blood activating biopotency was significantly correlated with the content of free anthraquinone (P<0.01). In summary, the combined use of multi-component simultaneous quantitative analysis and bioassay can achieve objective quantification and more comprehensive reflection on overall quality difference among different batches of rhubarb dispensing granules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19540/j.cnki.cjcmm.2017.0118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis.
Semin Arthritis Rheum
October 2024
Section of Rheumatology, Boston University Chobanian & Avedisian School of Medicine, VA Boston Healthcare System, Boston, MA, USA.
Background: Whether tumor necrosis factor inhibitor (TNFi) use is cardioprotective among individuals with radiographic axial spondyloarthritis (r-axSpA), who have heightened cardiovascular (CV) risk, is unclear. We tested the association of TNFi use with incident CV outcomes in r-axSpA.
Methods: We identified a r-axSpA cohort within a Veterans Affairs database between 2002 and 2019 using novel phenotyping methods and secondarily using ICD codes.
Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Semin Arthritis Rheum
February 2024
Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Background: To compare persistence of disease-modifying antirheumatic (DMARDs), with a focus on Janus kinase (JAK) inhibitors in Australian rheumatoid arthritis (RA) patients.
Methods: A retrospective observational study was conducted among 4,521 RA patients (females n=3,181 [70.4%]), using data from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset, aged ≥18 years and initiating a DMARD between 2011 to 2021.
Racial differences in persistent glucocorticoid use patterns among medicaid beneficiaries with incident systemic lupus erythematosus.
Semin Arthritis Rheum
February 2023
Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, United States; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
Objective: Glucocorticoids ("steroids") are frequently used in systemic lupus erythematosus (SLE). Prolonged use may contribute to racial/ethnic disparities in avoidable adverse outcomes. We examined racial/ethnic differences in longitudinal patterns of steroid use and dose.
View Article and Find Full Text PDFRisk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
Ann Rheum Dis
February 2023
Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, Île-de-France, France.
Article Synopsis
- The study aimed to compare the risks of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) between patients using Janus kinase inhibitors (JAKi) and adalimumab for rheumatoid arthritis.
- A large cohort of 15,835 patients from France was analyzed, finding that the risk of MACEs and VTEs for those on JAKi was not significantly different from those on adalimumab.
- Overall, the results provide reassurance regarding the cardiovascular safety of JAKi in comparison to adalimumab, even for patients with pre-existing cardiovascular risk factors.
Incidence, sociodemographic factors and treatment penetration of rheumatoid arthritis and psoriatic arthritis in Norway.
Semin Arthritis Rheum
October 2021
Division of Rheumatology and Research, Diakonhjemmet Hospital, Diakonveien 12, Oslo 0370, Norway.
Objectives: To evaluate nationwide incidence, sociodemographic associations and treatment penetration of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in Norway.
Methods: The study combined data from nationwide registries on the total Norwegian adult population (age ≥ 18). From the Norwegian Patient Registry, incident RA and PsA cases during 2011-2015 were identified with records of first and second healthcare episodes listing RA/PsA diagnostic codes, and ≥ 1 episode in an internal medicine or rheumatology unit with RA/PsA code during the two-year period after the first episode.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!